Obstetrics. & Gynecology

Permanent URI for this communityhttps://repository.ui.edu.ng/handle/123456789/525

Browse

Search Results

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Society of obstetrics and gynecologOkapani, A.y of Nigeria – clinical practice guidelines: guidelines for the prevention of cervical cancer
    (Wolters Kluwer - Medknow, 2019) Ezechi, O. C.; Okusanya, B. O.; Aimakhu, C. O.; Adesina, O. A.; Ohihoin, A. G.; Usman, H. A.; Umeora, O. U.; Akinola, R. I.; Anorlu, R.; Sagay, S. A.; Audu, B.; Fasubaa, O.; Oguntayo, B. A.; Awolude, O. A.; Ezeanochie, M.; Fawole, A.; Ijaiya, M.; Onyebuchi, A.; Dattijo, L.; Osagie, O. E.; Fabanwo, A.; Iketbuson, F.; Fawole, A. O.; Afolabi, B.; Agbogoroma, C.; Sadauki, H.; Okapani, A.; Yakasai, Y.; Muthir, J.; Okonta, P.
    Clinical practice guidelines have been developed by professional societies globally. Each guideline although based on published scientific evidence reflected each country’s socioeconomic peculiarities and unique medical environment. The Society of Obstetrics and Gynaecology of Nigerian has published guidelines in other clinical areas; however, this is the first edition of practice guidelines for the prevention of cervical cancer. The Guidelines Committee was established in 2015 and decided to develop the first edition of this guideline following Delphi pool conducted among members which selected cervical cancer prevention as the subject that guideline is urgently needed. These guidelines cover strategies for cervical cancer prevention, screening, and management of test results. The committee developed the draft guideline during a 2‑day workshop with technical input from Cochrane Nigeria and Dr. Chris Maske, Lancet Laboratories, South Africa. The recommendations for each specific area were developed by the consensus, and they are summarized here, along with the details. The objective of these practice guidelines is to establish standard policies on issues in clinical practice related to the prevention of cervical cancer.
  • Thumbnail Image
    Item
    Multimoda hyperspectroscopy screening in women at risk of cervical cancer: results of a pilot study in a developing country
    (Wolters Kluwer - Medknow, 2017) Awolude, O. A.; Akinwunmi, B. O.; Adewole, I. F.
    Background: Screening and treatment of pre-cancerous lesions is important for prevention of cervical cancer. Currently, most available screening tests for cervical cancer are limited by low sensitivity, prohibitive costs, logistics and technical concerns. This study evaluates the role of multimodal hyperspectroscopy (MHS) as a cost-effective, sensitive and user-friendly point-of-care machine for early detection in women at risk of pre-cancer lesions. Materials and Methods: Multimodal hyperspectroscopy of the cervix using the LuViva® Advanced Cervical Scan was performed first in a 1-minute procedure among 100 previously screened for cervical cancer using either visual inspection after application of acetic acid (VIA) or cytology within the last 120 days. This was then followed by obtaining human papilloma virus (HPV) samples and biopsies from women for histology. Results: Of the 22 women with abnormal Pap tests of at least low‑grade squamous intraepithelial lesion, 3 had CIN2+, 6 had CIN1, 4 were free of dysplasia at histopathology while 9 had cervicitis. All 3 of the CIN2+ recorded high likelihood of CIN2+ by MHS. However, HPV was negative for all 3 women. The machine classified 1 of 1 CIN1s and 7 of the 13 women without dysplasia or cervicitis as low or moderate risk for CIN2+ (40% specificity); of the 37 women who were VIA+, 81% were classified as high risk, and 66% of 37 women with normal Pap tests and biopsy were either at moderate or low risk. Conclusions: The findings from this pilot study show that MHS reduced the percentage of unnecessary colposcopy and biopsy by 37.5%. It was also able to differentiate between VIA+ and Pap negative women suggesting its potential of being a point-of-care primary and objective screening test.
  • Thumbnail Image
    Item
    Consensus recommendations for the prevention of cervical cancer in Sub-Saharan Africa
    (2013) Adewole, I. F.; Abauleth, Y. R.; Adoubi, I.; Amorissani, F.; Anorlu, R. I.; Awolude, O. A.; Botha, H.; Byamugisha, J. K.; Cisse, L.; Diop, M.; Doh, S.; Fabamwo, A. O.; Gahouma, D.; Galadanci, H. S.; Githanga, D.; Magure, T. M.; Mabogunje, C.; Mbuthia, J.; Muchiri, L. W.; Ndiaye, O.; Nyakabau, A. M.; Ojwang, S. B. O.; Ramogola-Masire, D.; Sekyere, O.; Smith, T. H.; Taulo, F. O. G.; Wewege, A.; Wiredu, E.; Yarosh, O.
    Cervical cancer is the second most common cancer and the leading cause of cancer-related death in women in sub-Saharan Africa. It is estimated that more than 200 million females older than 15 years are at risk in this region. This paper highlights the current burden of cervical cancer in sub-Saharan Africa, reviews the latest clinical data on primary prevention, outlines challenges in the region, and offers potential solutions to these barriers. Based on these factors, clinical recommendations for the prevention of cervical cancer from the sub-Saharan African Cervical Cancer Working Group expert panel are presented.
  • Thumbnail Image
    Item
    Routine antenatal syphilis screening In South West Nigeria- a questionable practice
    (Association of Resident Doctors, University College Hospital, Ibadan, Nigeria, 2010-06) Adesina, O.; Oladokun, A.
    Backgroud: Untreated maternal syphilis is strongly associated with adverse birth outcomes, especially in women with high titre syphilis. The WHO recommends routine serological screening in pregnancy. Some workers have advised a reappraisal of this practice, having demonstrated low sero-prevalence in their antenatal population. In view of this, the aim of this study was to determine the seroprevalence of syphilis in the antenatal population presenting at a major hospital in south-west Nigeria. Methods: This was a cross sectional study of healthy pregnant Nigerian women attending Adeoyo Maternity Hospital in the capital of Oyo State. The case record of every pregnant woman presenting for their first antenatal clinic visit over a 4-month period (September 1st to December 31st 2006) was reviewed. Results: During the study period, two thousand six hundred and seventy-eight women sought antenatal care. Three hundred and sixty-nine women (369; 13.4%) had incomplete records and were excluded from analysis. The records of the 2,318(86.6%) women with adequate records were subsequently reviewed. The mean age of the women was 27.4 years (± 5.34) and the mean gestational age 26.4 weeks (±6.36). The modal parity was 0. Only three patients were found to be reactive for syphilis giving a prevalence of 0.13%. Conclusion: The sero- prevalence value in this study is quite low and may justify the call to discontinue routine antenatal syphilis screening. However, a more rigorous screening program using diagnostic tests with higher sensitivity maybe necessary before jettisoning this traditional aspect of antenatal care.